Polaris Capital Management LLC lifted its position in shares of Quest Diagnostics Inc (NYSE:DGX) by 7.8% in the third quarter, according to its most recent disclosure with the SEC. The institutional investor owned 427,379 shares of the medical research company’s stock after buying an additional 30,882 shares during the quarter. Quest Diagnostics comprises 2.3% of Polaris Capital Management LLC’s holdings, making the stock its 15th biggest position. Polaris Capital Management LLC’s holdings in Quest Diagnostics were worth $46,118,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Principal Financial Group Inc. grew its stake in shares of Quest Diagnostics by 23.1% during the first quarter. Principal Financial Group Inc. now owns 436,117 shares of the medical research company’s stock worth $43,743,000 after purchasing an additional 81,936 shares in the last quarter. Xact Kapitalforvaltning AB boosted its stake in Quest Diagnostics by 5.4% in the second quarter. Xact Kapitalforvaltning AB now owns 33,548 shares of the medical research company’s stock valued at $3,688,000 after acquiring an additional 1,711 shares in the last quarter. Prospera Financial Services Inc acquired a new position in Quest Diagnostics in the second quarter valued at $228,000. Amalgamated Bank boosted its stake in Quest Diagnostics by 2.7% in the second quarter. Amalgamated Bank now owns 17,467 shares of the medical research company’s stock valued at $1,920,000 after acquiring an additional 462 shares in the last quarter. Finally, Nisa Investment Advisors LLC boosted its stake in Quest Diagnostics by 1.3% in the second quarter. Nisa Investment Advisors LLC now owns 37,587 shares of the medical research company’s stock valued at $4,132,000 after acquiring an additional 500 shares in the last quarter. 86.00% of the stock is owned by institutional investors.

Shares of NYSE:DGX opened at $94.26 on Tuesday. Quest Diagnostics Inc has a one year low of $90.31 and a one year high of $116.49. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.15 and a quick ratio of 1.09. The stock has a market capitalization of $13.04 billion, a PE ratio of 17.46, a price-to-earnings-growth ratio of 1.73 and a beta of 0.90.

Quest Diagnostics (NYSE:DGX) last announced its earnings results on Tuesday, October 23rd. The medical research company reported $1.68 EPS for the quarter, meeting analysts’ consensus estimates of $1.68. Quest Diagnostics had a net margin of 11.30% and a return on equity of 15.71%. The business had revenue of $1.89 billion during the quarter, compared to analysts’ expectations of $1.95 billion. During the same period in the prior year, the company earned $1.38 earnings per share. The business’s revenue was up 1.8% compared to the same quarter last year. As a group, sell-side analysts predict that Quest Diagnostics Inc will post 6.56 EPS for the current year.

DGX has been the subject of several research analyst reports. Bank of America initiated coverage on shares of Quest Diagnostics in a research note on Friday, October 19th. They issued a “buy” rating for the company. Argus set a $106.00 price objective on shares of Quest Diagnostics and gave the company a “buy” rating in a research note on Wednesday, October 24th. Canaccord Genuity decreased their price objective on shares of Quest Diagnostics from $118.00 to $105.00 and set a “buy” rating for the company in a research note on Wednesday, October 24th. Citigroup decreased their price objective on shares of Quest Diagnostics from $112.00 to $104.00 and set a “neutral” rating for the company in a research note on Wednesday, October 24th. Finally, JPMorgan Chase & Co. decreased their price objective on shares of Quest Diagnostics from $114.00 to $107.00 and set a “neutral” rating for the company in a research note on Wednesday, October 24th. Eight investment analysts have rated the stock with a hold rating and eleven have given a buy rating to the company’s stock. The stock has an average rating of “Buy” and an average target price of $111.13.

TRADEMARK VIOLATION NOTICE: “Polaris Capital Management LLC Boosts Stake in Quest Diagnostics Inc (DGX)” was originally reported by Daily Political and is owned by of Daily Political. If you are viewing this news story on another site, it was copied illegally and republished in violation of international trademark & copyright laws. The legal version of this news story can be read at https://www.dailypolitical.com/2018/11/20/polaris-capital-management-llc-boosts-stake-in-quest-diagnostics-inc-dgx.html.

About Quest Diagnostics

Quest Diagnostics Incorporated provides diagnostic testing information and services in the United States and internationally. The company's Diagnostic Information Services business segment develops and delivers diagnostic testing information and services, such as routine testing, non-routine and advanced clinical testing, gene-based and esoteric testing, anatomic pathology, and other diagnostic information services.

Featured Article: Short Selling Stocks, A Beginner’s Guide

Want to see what other hedge funds are holding DGX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Quest Diagnostics Inc (NYSE:DGX).

Institutional Ownership by Quarter for Quest Diagnostics (NYSE:DGX)

Receive News & Ratings for Quest Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quest Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.